



April 29, 2015

The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor Plot No. C1, 'G' Block, Bandra-Kurla Complex Bandra (East), Mumbai 400 051.	BSE Limited Floor 25, P.J. Towers Dalal Street Mumbai 400 001.
--	---

Dear Sirs,

Sub: Outcome of Board Meeting held on April 29, 2015

(Scrip Code: RPGLIFE / 532983)


This is to inform that the Board of Directors at its meeting held on April 29, 2015 has -

- 1) approved the enclosed audited financial results for the year ended March 31, 2015.
- 2) recommended an equity dividend of Rs.0.80 per share (10%) for the year ended March 31, 2015, subject to the approval of the shareholders at the ensuing Annual General Meeting.

Kindly take the above on your record.

Thanking you,

Yours faithfully,
For RPG Life Sciences Limited


Rajesh Shirambekar
Head - Legal & Company Secretary



Encl: As above

RPG LIFE SCIENCES LIMITED

(Rs. In lakhs)					
PART I					
STATEMENT OF STANDALONE AUDITED RESULTS FOR THE YEAR ENDED 31st MARCH, 2015					
Particulars	3 months ended			Year ended	
	31.3.2015	31.12.2014	31.3.2014	31.3.2015	31.3.2014
	Unaudited			Audited	
1. Income from Operations					
(a) Net Sales/Income from Operations (Net of Excise Duty)	6,119	5,648	5,114	23,308	22,938
(b) Other Operating Income	557	184	182	919	617
Total Income from Operations (Net)	6,676	5,832	5,296	24,227	23,555
2. Expenses					
(a) Cost of Materials Consumed	1,222	1,429	1,342	5,920	6,581
(b) Purchases of Stock-in-Trade	505	598	370	2,378	1,943
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	389	(90)	128	171	(849)
(d) Employee Benefits Expense	1,730	1,683	1,496	6,866	6,218
(e) Depreciation and Amortisation Expense	304	306	273	1,136	1,061
(f) Provision for Doubtful Debts and Advances (Net) [Refer Note 5]	63	(404)	(28)	(323)	689
(g) Other Expenses	1,921	1,991	1,748	7,798	7,805
Total Expenses	6,134	5,513	5,329	23,946	23,448
3. Profit/(Loss) from Operations before Other Income, Finance Costs and Exceptional Items	542	319	(33)	281	107
4. Other Income	-	36	18	91	236
5. Profit/(Loss) from Ordinary Activities before Finance Costs and Exceptional Items	542	355	(15)	372	343
6. Finance Costs	72	88	39	272	260
7. Profit/(Loss) from Ordinary Activities after Finance Costs but before Exceptional Items	470	267	(54)	100	83
8. Exceptional Items	-	-	(12)	-	6,414
9. Profit/(Loss) from Ordinary Activities before Tax	470	267	(66)	100	6,497
10. Tax (Credit)/Expense (including Deferred Tax)	-	14	(15)	-	1,157
11. Net Profit/(Loss) for the period	470	253	(51)	100	5,340
12. Paid-up Equity Share Capital (Face Value Rs. 8 each)	1,323	1,323	1,323	1,323	1,323
13. Reserves excluding Revaluation Reserves (as per last audited Balance Sheet)				11,193	11,253
14. (Loss)/Earnings per Share (of Rs. 8 each) (not annualised):					
(a) Basic	3.04	1.53	(0.31)	0.60	32.29
(b) Diluted	3.04	1.53	(0.31)	0.60	32.29



RPG LIFE SCIENCES LIMITED

PART II

Select Information for the Quarter and Year ended 31st March, 2015

Particulars	3 months ended			Year ended	
	31.3.2015	31.12.2014	31.3.2014	31.3.2015	31.3.2014
	Unaudited			Audited	
A PARTICULARS OF SHAREHOLDING					
1. Public Shareholding					
- Number of Shares	5,591,135	6,312,564	6,380,451	5,591,135	6,380,451
- Percentage of Shareholding	33.81	38.17	38.59	33.81	38.59
2. Promoters and Promoter Group Shareholding					
(a) Pledged/Encumbered					
- Number of Shares	-	-	-	-	-
- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	-	-	-	-	-
- Percentage of Shares (as a % of the total Share Capital of the company)	-	-	-	-	-
(b) Non-Encumbered					
- Number of Shares	10,944,790	10,223,541	10,154,790	10,944,790	10,154,790
- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	100.00	100.00	100.00	100.00	100.00
- Percentage of Shares (as a % of the total Share Capital of the company)	66.19	61.83	61.41	66.19	61.41


Particulars	3 months ended 31.03.2015
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	-
Received during the quarter	4
Disposed of during the quarter	4
Remaining unsolved at the end of the quarter	-

Notes:

1. Standalone Statement of Assets and Liabilities

(Rs. in lakhs)

Particulars	As at 31.3.2015	As at 31.3.2014
A EQUITY AND LIABILITIES		
1. Shareholders' Funds		
(a) Share Capital	1,323	1,323
(b) Reserves and Surplus	11,193	11,253
Sub-total - Shareholders' Funds	12,516	12,576
2. Non-Current Liabilities		
(a) Long-term Borrowings	32	36
(b) Deferred Tax Liabilities (Net)	-	170
(c) Other Long-term Liabilities	266	306
(d) Long-term Provisions	158	142
Sub-total - Non-Current Liabilities	456	654
3. Current Liabilities		
(a) Short-term Borrowings	3,246	1,368
(b) Trade Payables	2,530	3,702
(c) Other Current Liabilities	664	519
(d) Short-term Provisions	279	788
Sub-total - Current Liabilities	6,719	6,377
TOTAL - EQUITY AND LIABILITIES	19,691	19,607
B ASSETS		
1. Non-Current Assets		
(a) Fixed Assets	10,524	10,689
(b) Long-term Loans and Advances	557	516
Sub-total - Non-Current Assets	11,081	11,205
2. Current Assets		
(a) Inventories	3,448	3,777
(b) Trade Receivables	4,061	3,634
(c) Cash and Bank Balances	72	70
(d) Short-term Loans and Advances	1,029	921
Sub-total - Current Assets	8,610	8,402
TOTAL - ASSETS	19,691	19,607





2. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 29th April, 2015.
3. The figures for the quarter ended 31st March, 2015 are the balancing figures between the audited financial results for the year ended 31st March, 2015 and the published unaudited financial results for the nine months ended 31st December, 2014.
4. The company is exclusively engaged in the pharmaceuticals segment.
5. Provision for Doubtful Debts and Advances (Net) includes credit of an amount of Rs. 414 lakhs recovered from a party towards which provision was created in the previous year. Accordingly, the provision has been reversed by the amount received.
6. Pursuant to the enactment of the Companies Act, 2013, effective 1st April, 2014, the management has evaluated and reassessed the useful life of its fixed assets. Consequent to such change, the charge on account of depreciation for the quarter is higher by Rs. 7 lakhs and for year ended 31st March, 2015 is higher by Rs. 37 Lakhs. Further, fixed assets of Rs. 1 lakh having no residual life as at 1st April, 2014, have been recognised in the opening balance of General Reserve.
7. Depreciation expense for the year ended 31st March, 2015 includes prior period credit of Rs. 56 lakhs representing impact of rectification in the classification and estimated useful life of certain fixed assets.
8. Exceptional Items for the previous year ended 31st March, 2014 comprise of profit of Rs. 6,172 lakhs on such sale of a portion of leasehold land and building thereon and the company's share of interest income of Rs. 242 lakhs earned on the sale consideration deposited by the buyer in an escrow account, jointly held in the name of the company and the buyer, till the execution of the sale deed. The amount of sale consideration and the company's share of interest income lying in the escrow account had been transferred to the company on the date of execution of the sale deed.
9. The Board of Directors of the company has recommended a normal dividend of Rs. 0.80 per share of Rs 8 each (10 %) for the year ended 31st March, 2015.
10. Figures for the prior periods have been regrouped/reclassified where necessary.

For RPG Life Sciences Limited

CT. Renganathan
Managing Director
Mumbai, 29th April, 2015

